If you think bolstering the pharmaceutical supply chain in the U.S. is a national priority, you could be wrong.
Just take a look at the sorry situation in Morgantown, W. Va.
A decades-old generic-drug manufacturing plant run by Viatris — which was created last fall through a merger of Mylan and Pfizer’s Upjohn unit — will close this week, eliminating more than 1,200 jobs. Another 200 or so will go next year. The production work is being sent overseas, mostly to India, where Mylan already operates several facilities.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.